Literature DB >> 11050584

The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms.

A Wahl1, J H Loge, I Wiklund, B R Hanestad.   

Abstract

BACKGROUND: The reduction of disability caused by psoriasis is an important issue in dermatology. It is thus important to assess the patients' appraisal of their health-related quality of life.
OBJECTIVE: The aim of the present study was to assess health-related quality of life among patients with psoriasis and to compare these estimates with population norms.
METHODS: The samples comprised 283 patients and 2323 control subjects representative of the general Norwegian population. Health-related quality of life was assessed by means of the SF-36.
RESULTS: Both demographic and clinical variables, such as age, gender, educational level, hospital setting, comorbidity, and physical symptoms, affected the different SF-36 scales among the patients. After adjustments had been made for age, gender, and educational level, it was seen that psoriasis patients reported significantly lower scores than the normal controls on all scales. The greatest difference was found on the role emotional scale. The smallest difference was found on the health transition scale.
CONCLUSION: These results show that psoriasis patients report poorer health-related quality of life than the general population. Therefore patient care of psoriasis must give attention to the impact of the disease on different life domains.

Entities:  

Mesh:

Year:  2000        PMID: 11050584     DOI: 10.1067/mjd.2000.107501

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  9 in total

1.  Subjective Health Complaints in Individuals with Psoriasis and Psoriatic Arthritis: Associations with the Severity of the Skin Condition and Illness Perceptions - A Cross-Sectional Study.

Authors:  Emma Charlott Andersson Nordbø; Geir Aamodt; Camilla Martha Ihlebæk
Journal:  Int J Behav Med       Date:  2017-06

2.  Effects on quality of life and psychosocial wellbeing in Chinese patients with keloids.

Authors:  Wensheng Lu; Haifeng Chu; Xiaodong Zheng
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

3.  Global quality of life in primary caregivers of patients with cancer in palliative phase staying at home.

Authors:  Ellen Karine Grov; Alv A Dahl; Sophie D Fosså; Astrid K Wahl; Torbjørn Moum
Journal:  Support Care Cancer       Date:  2006-03-08       Impact factor: 3.603

4.  Biologics in the management of psoriasis.

Authors:  Jennifer D Bahner; Lauren Y Cao; Neil J Korman
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-07-23

5.  The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.

Authors:  Richard Shikiar; Mary Kaye Willian; Martin M Okun; Christine S Thompson; Dennis A Revicki
Journal:  Health Qual Life Outcomes       Date:  2006-09-27       Impact factor: 3.186

6.  Quality of life in psoriatic patients: a study using the short form-36.

Authors:  Abbas Darjani; Abtin Heidarzadeh; Javad Golchai; Shahrivar Sadr-Eshkevari; Narges Alizadeh; Maryam Arami; Nahid Nichhah
Journal:  Int J Prev Med       Date:  2014-09

7.  Self-management in daily life with psoriasis: an integrative review of patient needs for structured education.

Authors:  Gitte Susanne Rasmussen; Helle Terkildsen Maindal; Kirsten Lomborg
Journal:  Nurs Res Pract       Date:  2012-12-06

8.  Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials.

Authors:  Richard Shikiar; Brian W Bresnahan; Stephen P Stone; Christine Thompson; John Koo; Dennis A Revicki
Journal:  Health Qual Life Outcomes       Date:  2003-10-08       Impact factor: 3.186

9.  Impact of moderate-to-severe psoriasis on quality of life in China: a qualitative study.

Authors:  Hua Zhong; Huan Yang; Zhuxin Mao; Xiaoyun Chai; Shunping Li
Journal:  Health Qual Life Outcomes       Date:  2021-12-24       Impact factor: 3.186

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.